Crossmark

Cost–Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand

Published Online: 2022-01-17

Published Print: 2022-03

Authors

Vareesangthip, Kriengsak

Deerochanawong, Chaicharn

Thongsuk, Dittaya

Pojchaijongdee, Nuch

Permsuwan, Unchalee https://orcid.org/0000-0002-6909-2789
Funding

Funding for this research was provided by:

AstraZeneca, Thailand
License Information

Text and Data Mining valid from 2022-01-17

Version of Record valid from 2022-01-17
More Information

Article History

Received: 24 November 2021

Accepted: 22 December 2021

First Online: 17 January 2022

Document is current